MRTX - Cardiff Oncology: A Breakout Darkhorse In The Booming K-Ras Market

• Cancer patients with K-Ras mutations comprise a large population with bleak prognosis and minimal treatment options.
• Recent breakthroughs in targeting only a small portion of K-Ras patients have made multibillion-dollar waves in the biotech sector.
• Despite failures from past competitors, Cardiff Oncology is showing early signs of previously unseen efficacy in K-Ras patients.
• Unlike current hot-topic K-Ras inhibitors that work for <10% of K-Ras patients, Cardiff's onvansertib may be "agnostic" to K-Ras mutation type, working in 100% of K-Ras mutant patients.
• At a sub-$1B valuation, Cardiff's early signs of Pan-K-Ras success appear underappreciated, with K-Ras comparators valued in the multiple billions despite targeting far smaller markets.

For further details see: